Dr. Ross Soo, from the National University Cancer Institute Singapore and Founding Co-Chair of IPTCC, underscores the significance of biomarker testing in tailoring diagnoses and treatments for patients with lung cancer. To advance therapeutic strategies and improve the worldwide practice of biomarker testing, Dr. Soo urges healthcare practitioners to participate in the survey before March 23, 2024.